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In some breeds of dog, specifically the Yorkshire Terrier, a genetic defect exists that 
causes a hepatic portosystemic shunt to form. A hepatic portosystemic shunt is a vessel that 
when present cause blood to bypass the liver, which is responsible for filtering waste from the 
digestive system and moving it out of the body. An implantable polymeric device was 
constructed that would slowly occlude the hepatic portosystemic shunt and force the blood to 
stop flowing through the bypassing vessel and flow through the vessel to the liver over 3-4 
months time.  
The portosystemic shunt occluder device consist of three polyoxymethylene components, 
a swelling hydrogel (poly (acrylic acid)), and a degrading copolymer – (Poly (lactide-co-
caprolactone)). The poly (acrylic acid) was used to move the piston component of the device 
upward to constrict the portosystemic shunt placed inside the device.  Eight milligrams of poly 
(acrylic acid) had a swelling ratio of 20.10 ± 1.63, a swelling rate of 0.071 mm/s
2
, and generated 
25mN of force.  Eight milli-Newtons is the amount of force that is produced by blood flowing in 
a four milli-meter diameter vessel.  
The degradation properties of two compositions of poly (lactide-co-caprolactone) (40 
percent lactide and 60 percent caprolactone; 86 percent lactide and 14 percent caprolactone) 
were analyzed and relationships were developed that would aid in determining the degradation 






temperature.  The poly (lactide-co-caprolactone) controlled the rate that the piston moved by 
providing a counter force to the poly (acrylic acid).  The poly (lactide-co-caprolactone) (40:60), 
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The hepatic portal system is the system by which the blood flows through veins that 
begin as capillary beds in the stomach, intestines, and spleen. As food passes through the 
stomach and the intestines, Figure 1, certain nutrients are absorbed from it into the portal system. 
Products excreted for digestion, such as bile acids, and produced by digestion, such as ammonia, 
can also be reabsorbed into the portal system as well. But as the nutrients are absorbed, the 
organs of the system also produce waste such as bile acids, ammonia, urea, and lipids. This waste 
is then deposited back into the blood. 
Blood constituents absorbed by the organs of the digestive system are filtered by the 
liver. In a normally functioning system, blood that is processed by the liver is devoid of the 
waste. In some dogs such as the Yorkshire terrier, a small breed of canine, they may lack the 
 







proper function of the liver at birth.
1 
The impaired liver therefore makes removal of toxins 
difficult.  
Function of the Liver 
The structure of the liver can be simply described as two inputs and one output. The 
blood in the circulatory system enters the liver by way of two sources: the hepatic portal vein, 
which transports oxygen deprived and nutrient rich blood, and the hepatic artery, which 
transports oxygen rich blood, Figures 2 and 3.  The portal vein is the main blood source to the 
liver, Figure 2. Portal blood is derived from the capillary beds present in the stomach, intestines, 
and the spleen, Figure 3 and 4. The portal vein is a combination between the superior mesenteric 
vein, which originates from the digestive visceral, and the spleenic vein, which comes from the 
spleen.  After the portal vein enters into the liver it expands back into the capillaries, which then 
release the blood into the liver and then filters the excess waste from the organs of the digestive 
system. The filtered blood is absorbed back into the capillaries which pool to form the hepatic 
veins, which drain into to the inferior vena cava, which flows to the heart and re-circulates the 
blood, Figure 4 and 5.    
Portosystemic Shunts 
A portosystemic shunt is a blood vessel that allows blood to bypass the liver, move 
directly into the inferior vena cava and heart, thus eliminating the participation of the liver. The 







Figure 2: Major Vessels of the Hepatic Portal System [4] 
 
 







Figure 4: Canine Circulatory System [3]  
 
 






















































 conversion, detoxification, and synthesis of glycogen. More importantly, the constitutive cells of 
the liver aid in the removal and storage of glucose from the blood, as well as lipids, vitamins, 
copper and iron. The liver also removes elements such as ammonia and converts it into a safer 
chemical form of nitrogen (i.e. urea), which is used to make proteins for cell growth and repair 
and also creates the kidney concentration gradient for urine production.  Excess ammonia is 
excreted from the body by way of the kidneys. The liver also acts as a filter to prevent toxins 
from reaching the heart that could lead to a potentially fatal condition of sepsis.  
In dogs, the ductus venosus is a large portosystemic shunt that circumvents the liver 
during fetal development.  Portosystemic shunts are classified based on three categories: method 
of development, structural integrity, and type of bypass.  The development of portosystemic 
shunts is classified as either congenital or acquired.  Congenital shunts are vascular abnormalities 
that are thought to occur with abnormal fusion or incomplete regression of embryonic abdominal 
vasculature during fetal development or failure of normal closure after birth.
6
 The ductus venous 
in normal dogs closes functionally within days and is structurally obliterated within 3 weeks post 
birth.  
Acquired portosystemic shunts occur as a response to improper function of the liver or 
liver disease.  For example, cirrhosis of the liver decreases its functionality and increases the 
blood pressure in the portal system.  Acquired shunts assist in diverting blood away from a 
nonfunctional liver and protect a damaged liver from further deterioration.  Congenital shunts are 






dogs such as Maltese, Irish Wolfhound, and particularly the Yorkshire Terrier. In a study 
conducted by Karen Tobias at the University of Tennessee College of Veterinary Medicine, a 
significant number of Yorkies seen in a 12 year period were diagnosed as having congenital 
portosystemic shunts, and that percentage has been increasing over the past 10 years. This study 
concluded that Yorkshire Terriers were 35.9 times more likely than other breeds to be born with 
portosystemic shunts. The reason for Yorkshire predisposition is attributed to the amount of 
inbreeding in the breed, hence why it is considered to be a hereditary disorder; but the 
mechanism of inheritance has yet to be elucidated.
6
 
Portosystemic shunts can be classified as extrapatic or intrahepatic, single or multiple, 
and congenital or acquired. Structural classifications are based on the relative position of the 
branching off of the shunt to the portal vein from the vena cava (Figure 6). If the base of the 
shunt begins at the main portal vein and then flows directly to the inferior vena cava, the shunt is 
classified as an extrahepatic portosystemic shunt (Figure 6(b)).  Typically, these shunts can 
achieve a diameter up to one centimeter in size. They theoretically develop from abnormal 
anastomoses of the vitelline veins with the cardinal vessels, which form the tributaries of the 
caudal vena cava and its prehepatic segment.
6 
If the base begins within the branching of the 
portal vein and flows to the inferior vena cava, then it is classified as an intrahepatic 
portosystemic shunt (Figure 6c). Intrahepatic portosystemic shunts are thought to develop from 




























Normal canine fetal hepatic structures (Figure 6(a)) are derived from the vitelline and 
umbilical veins. In the fetus, fusion and degeneration of various sections of these vessels leads to 
the formation of the hepatic sinusoids, portal system, and the fetal ductus venosus, which are 
necessary for proper circulation and filtering of the blood.7 It should be noted that environmental 
and genetic factors alone or in combination are theoretically thought to be responsible for shunt 
development in canines, such as those which can be seen in Figure 7.  
Portosystemic shunts are also classified by if there are single or multiple shunts present in 
the system, Figure 8.  For the purposes of this research, discussion will be restricted to the most 
common portosystemic shunt in small canines, congenital extrahepatic single shunts.  
To understand the nature of congenital portosystemic shunts, it is necessary to understand 
their formation.  Fetal development begins with formation of the zygote.  Pregnancy is divided 
into three periods: the germinal period, the embryonic period and the fetal period.  After 
fertilization, the blastocytes begin separation into the three main layers: endoderm, mesoderm, 
and ectoderm. The circulatory system develops out of the mesoderm layer.  During the germinal 
period, the basic structure of the mesoderm layer begins to form. 
Next the embryonic period marks the stage of organ development on a broad scale.  
Because the organs are not fully developed, organ systems such as the circulatory system are not 
capable of supporting the other organ systems through their own facilitation.  Thus, the other 
developing systems (i.e. skeletal and muscle) rely on the mother’s circulatory system to provide 








Figure 7: Portosystemic Shunt in Canine 
 







venosus allow the developing blood flow to bypass other developing and partially functional 
organs.  At this point in the fetal development, the organ systems that are within the fetus cannot 
fully operate, and consequently, the fetus is dependent upon the mother’s working organs.  
Shunts provide a way of directing blood away from not fully functional organs. The components 
of the plasma (water, electrolytes, and proteins) are transferred to the fetus from the mother via 
the umbilical cord, because at this stage the heart and liver of the fetus are not fully functional. 
The mother’s liver does the work of filtering out toxins, storing sugar, and producing protein for 
the unborn fetus. Therefore, these shunts are necessary to avoid disturbing the developing liver 
of the fetus and to deliver the filtered blood nutrients to the fetus from the properly working 
organs of the mother.
8,9
  During the fetal period, the organs more fully develop, and the fetus 
becomes less dependent upon the mother’s organs.  After birth, these shunts close to allow the 
neonate to rely upon its own body functions independently of the mother. But in some situations 
shunt closure does not occur.    
In the past, there have been a number of approaches used to occlude these extrahepatic 
shunts.  In the early 1990’s, surgical ligation was the recommended treatment for congenital 
portosystemic shunts.
10
 However, this simple technique has experienced many setbacks.  
Mortality rates associated with surgical ligation reached percentages as high as 21%.
10
   
Complications due to this intervention included portal hypertension, anesthetic complications, 
portal vein thrombosis, or status epilepticus.
10
  






demeanor, and behavioral abnormalities (circling, disorientation, unresponsiveness, staring into 
space, head pressing) are common symptoms of dogs with extrahepatic shunts present.  Dogs 
with extrahepatic shunts normally have low blood urea nitrogen (BUN) and albumin 
concentrations, display microcytosis (a condition where red blood cells are smaller than normal), 
or acutely anemic. These blood related abnormalities permit diagnosis via blood analysis.  The 
urine analysis is also a method for detection.  The amount of liver enzymes aspartate 
aminotransferase (AST) and alanine aminotransferase (ALT) increases in dogs with congenital 
portosystemic shunts resulting in small spiky crystals (ammonium biurate) in their urine also. 
Though the previously mentioned symptoms/characteristics are visible in subjects with shunts 
present, they are not specific to the presence of a liver shunt. Veterinarians use these 
abnormalities as signs that a shunt could be the possible reason for the animal’s poor health.  The 




Shunts can be treated with proper diet and medication, but only approximately one third 
of the dogs medically treated will meet their average life expectancy. Over half the dogs that are 
treated medically are euthanized within 10 months of being diagnosed because of neurologic 
related problems, such as seizures and behavioral changes, or progressive liver damage.
9
  
Many of the toxins produced in the intestines are due to the protein intake, therefore it is 
important to reduce the amount of protein in the dog’s diet. Food for adults dogs and puppies 






byproducts. Dogs with shunts are restricted to high quality proteins made from vegetables or 
milk that contains 18%-22% protein or less on a dry matter basis. The diet should also be rich in 
antioxidants and vitamins, low in iron and copper, and easily digestible.
9
 
One of the main medications that is prescribed to control the side effects of the shunt 
being present is Lactulose, a disaccharide (fructose-galactose) solution that promotes diarrhea, 
reducing the absorption of toxins.
9
 Intestinal bacteria produce most of the toxins that are 
absorbed by the intestines.  Lactulose changes the pH in the large intestines, decreases the 
adsorption of ammonia and other toxins in addition to making the environment uninhabitable for 
the bacteria that produces the toxins.
9
  
In cases where the clinical signs are not controlled with the diet and/ or lactulose, the 
veterinarian will normally prescribe antibiotics to reduce the number of toxin- producing bacteria 
present in the intestines. Although diet and medicine are valid treatments the most effective 
treatment that provides the best chance for a long and healthy life is surgery.
9
  
Procedures for Shunt Occlusion 
Silk Suture Ligation  
A few investigators have reported successful occlusion of the congenital portosystemic 
shunt, using a silk suture. Additional studies claim that complete occlusion is not controllable 
using silk sutures.
11
 Silk, a non-absorbable material, is capable of inducing an inflammatory 
response within a vessel wall. This is thought to be partially responsible for the occlusion effect 






shunt being present. Initially activated by the degranulation of the neutrophils a chronic 
inflammation response (consisting of fibroblast infiltration, proliferation, and scar formation) 
gradually occludes the vessel primarily around the time of application of the sutures.
11,12
 In a 
study conducted by Youmans and Hunt, in which they tested the four primary vascular occlusion 
methods ( Ameroid constrictors, cellophane, silk sutures, and transverse coil embolization) they 
noted that silk sutures were the only method that failed to completely constrict the vein that was 
being shrunk (attenuated) within a 6 week period.
13
  
There are many factors that are thought to play a part in the rate of partial occlusion with 
silk sutures: the degree of inflammation produced by perivascular dissection, excessive 
manipulation of the vessel during surgery, postoperative vasospasms, as well as the diameter of 
the suture being utilized.
11,12,13
 The advantages of using silk sutures as a treatment are (a) the 
accessibility; (b) low cost, and (c) flexibility for application to both extrahepatic and intrahepatic 
congenital portosystemic shunts. The disadvantages associated of silk sutures are: (a) require 
measurement of intraoperative portal pressure during ligation; (b) potential secondary surgeries; 




Cellophane is derived from plant cellulose and it has a variety of purposes ranging from 
reconstructive knee surgery to the attenuation of single extrahepatic shunts. The use of 
cellophane bands for the attenuation of shunts in dogs began in since 1990. Sheets of sterile 






the band is placed around the shunt. The cellophane initiates an inflammatory reaction around 
the vessel that is generally associated with a chronic foreign body response. The inflammation 
leads to gradual occlusion of the enclosed vessel.
15,16,17
 The use of cellophane banding to occlude 
congenital extrahepatic portosystemic shunts is one of two methods currently accepted.  
Treatment using cellophane is quick, inexpensive, with a long constriction time thereby 
decreasing the chance of the developing portal hypertension.
15,16,17
 
In a study conducted by Frankel et al. on 32 dogs, 18 cases evaluated retrospectively and 
14 dogs evaluated prospectively, the results of the cellophane banding of the vessels showed the 
technique resulted in complete occlusion of the attenuated vessels to a diameter 2.5 mm from an 
initial diameter of 6.8 ± 1.4 mm diameter within an 8 week period. Vessels of an attenuated 
diameter of 3.0 mm did not have 100% occlusion.
16
 They analyzed the results by reviewing the 
medical history, hematologic and serum biochemical analyses, abdominal ultrasonography, and 
portal angiography of the dogs. Frankel concluded that cellophane was a useful method in the 
occlusion of vessels smaller than a 3 mm diameter.  
Transvenous Coil Embolization 
Transvenous coil embolization (TCE) is a process in which a coil (spring) is placed into a 
shunt for gradual occlusion. A sheath is placed into the right jugular vein and a guided wire is 
inserted into the sheath until it reaches the shunting vessel at which a stainless steel coil is 
released to gradually occlude the vessel.
14,15
 The TCE method is less invasive and a more 






the down side to the process is that there are limited reports of successful treatments, especially 
in small breeds of dog.
14,15  
Asano et al. have been successful in the application of TCE. They 
tested the use of the transverse coil in a 3-month-old Miniature Dachshund. Two weeks after 
implanting the 8-mm diameter coil in the 6 mm diameter vessel they noticed a reduction in the 
serum bile acid levels and eventually complete occlusion after 4 months. The follow up study 
conducted 3 years post implantation showed none of the associated clinical signs (decreased 
function of the liver, weight loss, or hypertension). Therefore they concluded that transverse coil 
embolization was successful, more so in larger breeds of dogs, after testing on a range of sizes.
14
   
Ameroid Constrictors 
An ameroid is hygroscopic compressed casein that swells when immersed in fluid.  The 
most effective treatment to date for gradual occlusion of a portosystemic shunt was done using 
an ameroid constrictor. A stainless steel cuff, to withhold the stresses related to the expansion 
(Figure 9), encases the occluder. The inner diameter of the shunt occluder was 5 mm, although 
they are commercially available in size ranging from 3 mm to 10 mm. The locking mechanism 
for the ameroid occluder (Figure 9) consists of a cylindrical peg, approximately 2 mm in 
diameter for insertion into the ameroid disc. The Ameroid’s swelling capabilities facilitate a tight 
fit between the ameroid and the lock. The placement of the Ameroid occluder in a surgical 
operation is shown in Figure 10. 
Results from original experiments using the occluder showed 14 % of the dogs died in 
the early postoperative period from portal hypertension.
10






technique, the ameroid constrictor produces a suitable decrease in problems such as portal 
hypertension, hemorrhage, or intractable seizures following recovery from anesthesia, which are 
associated in up to 50% of dogs post-ligation. 
 
In an experiment conducted by Vogt, they observed early rapid expansion during the first 
14 days after implantation followed by 2 months of slow expansion.
10
 Inou et. al also conducted 
a study to measure the expansion of an ameroid occluder. They recorded in the in-vitro study that 
the ameroid expanded rapidly to 6% stenosis during the 24-hour period after immersion into 
saline. The stenosis progressed slowly thereafter to 9% and 14% after 20 and 30 days 
respectively. For the in-situ study the coronary stenosis progressed to 57 ± 14% (mean ± SD), 78 
± 14%, and 58 ± 10% on the 10th, 20th, and 30th day post ameroid implantation (Figure 11).
18,19
   
It was suggested that a more gradual approach to occlusion of the portosystemic shunt, 
possibly 3 to 4 months, would be beneficial to the dog. Establishing a slower pressure change is 
the main goal of this type of treatment. By having a slower gradual occlusion the pressure 
change in the shunt is slowly changed, decreasing the major problems associated with rapid 
vessel closure.
6










































The aforementioned shunt occluder designs (Ameroid occluder, silk ligation, and 
cellophane banding techniques) all have flaws leading to outcomes that ranged from partial 
occlusion to rapid occlusion and associated postsurgical issues such as hypertension. The goal of 
this study is to design a new occluder that eliminates the problems associated with current 
devices/ procedures. The proposed design is based on the use of hydrogels and degradable 
polymers.  
Hydrogels  
Hydrogels are classified as crosslinked polymeric structures that swell during water 
adsorption. They are normally made via a free radical polymerization mechanism, where 
monomer units are connected into long chains through their double bonds. Crosslinking agents, 
monomers with two or more double bonds, provide a polymer network structure by connecting 
the long linear polymer chains. The crosslinked polymer chains contains either covalent bonds, 
physical crosslinks from entanglements, association bonds, or strong van der Waals interactions 
between chains.
21
 Hydrogels are classified into four categories: (i) homopolymer hydrogels, (ii) 
copolymer hydrogels, (iii) multipolymer hydrogels, and (iv) interpenetrating polymeric 
hydrogels. The classification is dependent on their method of preparation, physical structure or 
ionic charge.
21
 Homopolymer-hydrogels are crosslinked networks of a single type of hydrophilic 






monomer units, of which one must be hydrophilic to render the hydrogel swellable.  
The degree of crosslinking in a polymeric network structure is a critical factor because it 
dictates the mechanical strength, swelling ratio, and many other properties of the polymer gel by 
influencing the molecular weight between crosslinks (Mc). The degree of crosslinking of a 
polymer is controlled by the fractionation of crosslinking agents present in the copolymerization 
and the double bond conversion in the reaction. Smaller amounts if crosslinking agent can lead to 
a less densely crosslinked hydrogel.  
The swelling of hydrogels is defined as the ratio of the volume of fluid to the volume of 








   Equation 1 
ESR is the water absorption (wt %). Wd and Ws are the weights of the samples in the dry 
and swollen states respectively.
62
 A polymer swells by water flowing into the spaces between 
chains, which are created by the repelling of the ionic charges. Equilibrium is reached when the 
polymer chains are separated by enough water molecules to negate their repulsive forces on each 
other.
24
 The Swelling rate is the amount of displacement the network experiences over time, 
Equation 2. 
SR is the swelling rate, ΔX is the change in displacement, and Δt is the change over time. 










  Equation 2 
Poly (Acrylic Acid) 
Polyacrylic acid (PAA) is a water soluble polymer. Its large absorbent capacity and non-
toxic nature makes it a common material for use in menstrual pads and diapers. PAA has the 
repeat unit molecular formula C3H4O2 and chemical structure depicted in Figure 12.  
The network formation of the PAA hydrogel is made by a free radical polymerization 
mechanism. The crosslinked structure of the ionic network is affected by the monomer 
concentration, pH, and ionic strength during polymerization. A hydrogel network formed from 
PAA has the ability to absorb many times their weight in water, or swell, and thus, is classified 
as a super absorbant. The ability of PAA to swell is made possible by the carboxylic acid groups 
on the polymer chain that associates strongly with water molecules. These types of group 
interaction are influenced by ionic strength and pH, therefore the swelling equilibrium of the 











The molecular weight between crosslinks (Mc) dictates the mechanical strength, the 
swelling ratio, and the swelling rate based on the length between the crosslinks. In the shunt 
occluder, PAA will be used as a source of force to drive a piston to close the shunt. The force is 
created by the expansion of the PAA when confined in a small compartment within the occluder.  
Poly (lactic acid) (PLA) 
Poly (lactic acid) (PLA) is a biodegradable linear polyester derived from lactic acid. The 
structure of PLA is shown in Figure 13. Poly (lactic acid) is synthesized through a ring-opening 
polymerization reaction (Figure 14). The methyl group adds to the more amorphous 
characteristic as well as the increase solubility in organic solvents. The most commonly used 
form is Poly(lactic acid) in the L-form -P(L)LA, which releases L-lactic acid, a component 
common of the body, when it degrades.
22
 
PLA degrades by homogeneous, hydrolytic erosion. Through hydrolysis and microbial 
action PLA breaks down into carbon dioxide and water. PLA usually degrades in a two stage 
process. In the first stage of degradation, the majority of the molecular weight loss occurs with 
some loss of tensile strength. In the second stage, the mass and tensile strength decrease 
significantly, generally when the number average molecular weight (Mn) is less than or equal to  
 








Figure 14: Reaction Scheme of Poly lactic acid [25] 
 
15000 g/mol. P(L)LA with a molecular weight of approximately 95000 g/mol degrades in vivo 
by 56% over approximately a 6 month time span based on peak molecular weight (Mp) analysis 
conducted by Wong. For Poly (DL Lactic acid) with a molecular weight of 58000 g/mol and 




The glass transition temperature of the PLA ranges from 51-59
o
C, the melting 
temperature ranges from 159-178
o
C, and the tensile modulus ranges between 1200-3000 MPa. 
The tensile strength, degradation rate, and the melting temperature are dependent on the weight 
average molecular weight and chemical structure (D or L structure).
25
 
Poly lactic acid can be processed like most thermoplastics, into fiber using conventional 






such as sutures and drug delivery devices. It is also being evaluated as a material for tissue 
engineering. Since it is biodegradable it can be used in the preparation of the biocompatible 
polymers, useful for producing loose-fill packing, compost bags, food packaging, and disposable 
tableware. 
PLA has many potential uses in the form of fibers and non-woven textiles, such as 
upholstery, disposable garments, awnings, feminine hygiene products, and diapers. It is an 
odorless polymer and is classified as GRAS (generally recognized as safe) by the Food and Drug 
Administration (FDA) in the United States. PLA can be synthesized to be either rigid or flexible. 
Lactic acid can be copolymerized with other monomers to control degradation. The 
mechanical properties of PLA, and its degradation behavior, make it an ideal polymeric 
candidate for implants in bone or soft tissue, and also for resorbable sutures. In summary, the 
mechanical, pharmaceutical, and degradation characteristics can be controlled by parameters 
such as chemical composition and molecular weight of the polymer.
26
 The time frame for 
resorption of the PLA and its copolymers may be as little as a few weeks or as much as a few 
years. Major criticism of the polymer is that it releases carbon dioxide and methane during its 
breakdown. 
Poly(glycolic acid) (PGA) 
Polyglycolic acid (PGA), Figure 15, is obtained from ring-opening polymerization of 
glycolide. PGA is a highly crystalline, hydrophilic, linear aliphatic polyester that is 
biodegradable. It has a melting point of 210
o







Figure 15: Poly (glycolic acid) chemical structure [25] 
 
organic solvents. PGA has a glass transition temperature (Tg) between 35 -40
o
C. The degree of 
crystallinity ranges between 46%-52% crystalline, depending on the crystallization temperature 
(TC) and molecular weight (Mw). 
PGA degrades mainly by bulk erosion. The erosion occurs by random hydrolysis of the 
ester bonds. Erosion of PGA is a bimodal process. In the first phase there is diffusion of water 
into the amorphous region which leads to hydrolysis. The second phase initiates after the water 
penetrates and starts to hydrolyze the crystalline regions.
43
  
PGA is used for the production of implantable medical devices and resorbable sutures. 
Surgical sutures made from PGA show mass loss mainly in the second phase when water 
penetrates into the amorphous region and complete degradation is achieved between 4 and 12 
weeks. The rate of degradation is affected by the pH of the environment, degree of crystallinity, 
and curing time.
25
 Degradation of PGA results in the production of glycolic acid which is non-









Poly (caprolactone) (PCL) 
Poly (caprolactone) (PCL), Figure 16, is a biodegradable semi-crystalline aliphatic 
polyester with a melting point of approximately 57
o





 PCL can be prepared by ring opening polymerization of ε-caprolactone. 
PCL is capable of forming copolymers and blends with a range of other materials. It 
degrades by hydrolysis of the ester linkages and enzyme, which makes it an appropriate 
biomaterial because these are methods of degradation in a biological environement.  
The degradation process occurs in two-stages. The molecular weight loss occurs in the 
first stage, by means of chain cleavage, and mass and strength loss occur in the second.
43
 The 
degradation products of PCL are water and carbon dioxide. It is being considered as a potential 
for long term implants, because of a slow degradation rate.
25
 PCL is used in drug delivery 
devices, sutures, adhesion barriers and is being investigated as a scaffold for tissue repair.  
Another application of PCL is a possible biodegradable contraceptive that can be placed under 
the skin. 
 








Figure 17: Poly (anhydride) chemical structure [25] 
 
Poly(anhydrides) 
Polyanhydrides are a hydrolytically unstable polymer. Polyanhydrides are characterized 
by the bonds that they have to the R group. They are usually either aliphatic, aromatic, or a 
combination of two. Polyanhydrides have been considered to be useful biomaterials as 
carriers of drugs to various organs of the human body.  A general structure of a polyanhydride is 
shown in Figure 17. Polyanhydrides are very biocompatible, can be prepared easily from low 
cost resources (such as dicarboxylic acid monomers with excess lactic anhydride), and can be 
chemically modified to meet desirable end use applications. They degrade in vivo into non-toxic 
di-acid counterparts that are eliminated from the body through one of the metabolic cycles. The 
hydrophilicity of polyanhydride copolymers makes them unique in terms of biodegradability. 
The anhydride bond is labile and rapidly hydrolyses in aqueous environments. However, water 
penetration within the core of the polymer matrix is generally not allowed due to the 




Poly (lactide-co-caprolactone), Figure 18, is a copolymer of lactic acid (LA) and epsilon-







Figure 18: Poly (lactide-co-caprolactone) chemical structure [28] 
 
epsilon caprolactone. The combination of these two polymers creates a biomaterial with more 
potential applications than each homopolymer. The copolymerization of the lactic acid with 
epsilon-co-caprolactone significantly increases its rate of degradation of the structure.  Also, 
biocompatibility is not an issue, as both copolymers have been proven to be extremely 
biocompatible.  
Poly (lactide-co-caprolactone) is not a widely used copolymer and does not have a known 
history of biomedical applications. Though each of the polymers that constitutes the copolymer 
are well known and historically used in biomedical applications, there is still a possibility of 
unexpected events such as adverse reactions, mechanical property breakdown, and other 
problems pertaining to concentration ratios. Using this polymer should entail a considerable 
amount of testing. Also, protocols will have to be created to ensure consistency once a 
concentration ratio is decided upon.   
Copolymers are a strong choice in biomaterials because they offer flexibility and the 
properties can be manipulated to meet specific needs. This is not only useful in controlling rates 






Copolymerization of two polymers extends control of the mechanical properties, including 
tensile strength and modulus. The effect that copolymerization has on each of the individual 
homopolymers is especially important. In the instance of poly (lactide-co-caprolactone), 
copolymerization of the PLA with PCL increases the rate of degradation of the copolymer by 
degrading the PLA portion of the copolymer faster and eroding the structure.   
The biodegradable polymer’s degradation rate is very important therefore calculations 
related to the composition of the polymers in the copolymer blend and molecular weights 
associated with the polymer, which both are associated with the rate of degradation, have to be 
determined to reach the goal of complete occluder constriction in 3 months. Further testing will 
be required to obtain specific information of the relationship between the swelling of the 
hydrogel and the degradation of the polymers, as depicted in Figure 18. The degradation of the 
polymer and swelling of the hydrogel must be controlled to the point where the swelling and 
degradation occur at complementary rates to cause the desired gradual occlusion. Poly (lactide-
co-caprolactone) seems to be the most appropriate degradable biomaterial for the new device 
design.   
Polyoxymethylene (Acetal) 
 Polyoxymethylene (Acetal), Figure 19, is a copolymer that is composed of Delrin (an 
acetal homopolymer) and BASF Ultraform, (a cyclic ether). Polyacetal resins are implantable 
high performance polymers that have high chemical and mechanical resistance. They are 
commonly used in joint replacement components and other long term implants.
30







Figure 19: Polyoxylmethelene chemical structure [29] 
 
mostly in a copolymerized form, has been used in in-vivo components, such as the Bjork-Shirley 
tilting disc mechanical heart valve, for more than 20 years.
31
 
The major advantage of having the copolymerized acetal is that it is stabilized. In 
homopolymer form the polyacetal tends to depolymerize and eliminate formaldehyde. The 
stabilization of the acetal is done by copolymerization with cyclic ether.
31
  
The key properties of Acetron (polyoxcymethylene) are that it has high mechanical 
strength, high modulus, high natural lubricity, excellent dimensional stability, and low moisture 
absorption. A few of its uses are for bearings gears, electrical components, fuel system parts, 
pulleys, anti-friction parts, and medical applications (i.e. bone joints and heart valves). Acteron 
would be ideal because of its machining properties, its biocompatibility, and its certification by 
the FDA, the USDA, NSF, Canada AG, and etc.  It has a melting temperature of 168.33
o
C, 
which is much higher than the temperature that it will be at in a biological environment (37
o
C). It 








 NOVEL DESIGN OF A PORTOSYSTEMIC SHUNT OCCLUDER  
 
The previous studies have shown some promise in helping occlude portosystemic shunts 
(Figure 6), but there are still complications due to the pressure changes that occur relatively 
quickly after the treatments.
11,12,14
 The goal of this project is to design a shunt occluder with 
variable occlusion rates. The initial objective is to design a device with a three-month linear 
occlusion rate that would allow more time for the dog’s circulatory system to adjust to the 
pressure changes caused by occlusion. 
Materials Specifications 
The material used for the shell of the device needs to be mechanically sturdy as well light 
in weight. The selected materials for the new occluder must maintain structural integrity 
throughout the life of the dog despite the (aqueous) environment in which it will be surrounded.  
The selected materials must not elicit unfavorable reaction therefore they must have well-
established biocompatibility in order to ensure the safety of the dog.  Furthermore, the material 
should be resistant to cell adhesion as this might impede the function of the device by blocking 
the occluder piston’s motion or by encapsulating the device. The same material will be used for 
the occluder’s piston. It needs to be smooth so as not to create friction to prevent the piston from 







The shell of the device was a simple design. The cylindrical shell is made of two parts 
that come together to encase the vessel, Figure 20.  This design allows for the surgeon to load the 
degrading polymer and swelling hydrogel into the device prior to surgery, which decreases actual 
surgery time. The cylinder diameter is varied based on the size of the portosystemic shunt that is 
to be placed in the vessel chamber. The casing is a polyoxymethylene material with the 
trademark name Acetron.  This material is used because of its FDA approved; it has sufficient 
mechanical strength, and can be machined with ease.    
Design 
The new portosystemic shunt occluder (Figure 20) consists of three different sections: a 
piston (Figure 21), a polymeric chamber (Figure 22), and a vessel chamber (Figure 23). For 
assembly, the vessel chamber snaps together with the polymeric chamber and the piston is 
suspended in between the two sections.  The vessel chamber, a “ U ” shaped component that can 
be seen in Figure 23, was designed for easy and comfortable placement of the shunt inside the 
device. 
The shape of vessel chamber decreases the possibility of pinching the targeted shunt 
vessel, which could lead to blood disruption. Rapid blood flow disruption was determined to be 
the reason that dogs with the Ameroid Occluder are at higher risk for hypertension, which leads 
to the 14% mortality rate associated with the device. Check this percentage with newer papers.  










(a)                  (b) 
Figure 20: Hepatic Portosystemic Shunt Occluder 











Figure 21: Occluder's Piston 
 
 



























degrading polymer) are loaded, Figure 22.  The third part of the device, the piston, was designed 
to have unidirectional motion. The piston makes contact with the shunt and is directly 
responsible for the occlusion. 
The material from which the device is being constructed is polyoxymethylene. The 
degrading polymer that is desired to control the piston’s motion was determined by its rate of 
degradation, the byproduct, and loading capabilities in the design. The swelling polymer, that is 
being used to provide the force necessary to close the shunt, was determined based on the 
possible force that would be generated to move the piston.   
Poly (DL lactide-co-caprolactone) (PLCL) was chosen as the degrading polymer because 
of its surface-eroding mode of degradation as well as its slow rate of degradation. The PLCL will 
be placed in the compartment adjacent to the swelling hydrogel, as can be seen in Figure 20. 
The PLCL slowly erodes to impart the force from the swelling polyacrylic acid hydrogel 
via the piston onto the vessel. Vert et al. found that the degradation of massive P(DL)LA and 
P(L) LA  specimens proceed more rapidly in the center than at the surface because of the 
concentration of carboxylic acid end groups.
32
 PCL, an aliphatic polyester, provides  good 
permeation for steroids. It has a long degradation time that ranges between 3-5 years.
32 
 
Block PLCL, originally synthesized by Feng et al., has both the advantages of the 
permeation rate of steroids and a degradation rate between that of the homopolymers (lactide and 








Ye et al. conducted experiments to determine the degradation rate of PLCL in a 
phosphate buffer solution at various temperatures and compositions. In Figure 24 the intrinsic 
viscosity was analyzed for various compositions at different time intervals. There is a semi-
logarithmic relationship between the intrinsic viscosity [η] of homo- or block copolymers and 






C. PCL (ο) 
as time progressed. As temperature increased the degradation rate increased. The intrinsic 




In a study using poly (lactide-co-caprolactone) (65:35) to make nerve guides. 80% of the 
polymer had degraded after four months. The ability to alter and control the rate of degradation  
 






using different molar ratios of each copolymer is a very appealing characteristic. Tailoring the 
degradation rate, and correlatively the occlusion rate, has the potential to eliminate previous 




Figure 25 is an overview of the procedures for the hepatic portosystemic shunt occluder’s 
testing. The three main sections are the device design, the polymer components, and the 
complete mechanical system testing. There are two polymers that are being examined: the 
swelling hydrogel polymer- Poly Acrylic Acid (PAA) and the degrading polymer-Poly (lactide-
co-caprolactone) (PLCL). The purpose of the PAA is to provide pressure to shift the piston that 
will be in contact with the portosystemic shunt. The purpose of the PLCL is to control the rate at 




























The PAA, the hydrogel for the experiment, was obtained from baby diapers. The 
degradation polymers, Poly (DL lactide-co-caprolactone) (86 mol % lactide [457647-5G] and 40 
mol% lactide [457639-5G]), were purchased from Sigma Aldrich. The molecular characteristics 
for the PAA and the Poly (DL lactide-co-caprolactone) are presented in Tables 1. 
Testing Procedure 
The following are the studies that were performed to determine if the chosen polymers 
experimentally had the desired characteristics (swelling ratio, generated pressure/force, and 
degradation rates). The swelling testing was conducted using the thermal mechanical analyzer 
(TMA) and the degradation studies were conducted using the gel permeation chromatographer 
(GPC). 
Degradation Studies 
The purpose of the degradation studies was to determine the rate by which the Poly 
(lactide-co-caprolactone) would molecularly degrade in an in vitro study that simulated a 














Table 1: Molecular characteristics of Poly (Lactide-co-caprolactone) and Poly Acrylic Acid 
Poly(D,L Lactide- co-
caprolactone) 86:14 
Poly(D, L Lactide -co- 
caprolactone) 40:60 
















0.7 -0.9 dL/g  
in chloroform (lit) 
Inherent Viscosity 
0.7 -0.9 dL/g 













Testing of Poly (lactide-co-caprolactone) (PLCL) 
Approximately 25 mg of the PLCL was placed into a phosphate buffer saline (PBS) 
solution that simulated a biological environment. The degradation rates were determined over a 6 
week period for two samples of the PLCL in PBS sample solutions: one at 37
o
C, the temperature 
of a biological specimen, and the other at 50
o
C to kinetically accelerate the degradation. 
Preparation of Buffer Solution  
Components: 
 Sigma Diagnostics- Phosphate Buffered Saline [pH 7.4 at 25oC] 
 Distilled water  
 1000mL container  
 Rubber stopper (for container) 
Procedure: 




 Verify the pH (with a Mettler Toledo Seven Multi pH meter with a Mettler Toledo 
InLab413 NTC tip 







 Place 20mL of PBS into a 50mL container 
 Place 20mg of PLCL into each solution 
 Place container into an oven at a constant temperature of 37oC 
 Place the second container into another oven at a constant temperature of 50oC 
 Test the Molecular weight of the PLCL in a vile (37oC and 50oC) every two weeks, 
for 8 weeks.  
Characterization Techniques 
Thermal Mechanical Analysis (TMA) 
The thermal mechanical analyzer (TMA) is an instrument that can be used to measure 
volumetric changes (the expansion or collapsing of a sample) in temperature controlled, 
atmospherically inert environment (Figure 26).  TMA studies can also be used to determine 
characteristics such as: the glass transition temperature (Tg), the swelling ratio, swelling rate, 
stress temperature relationships, and pressures produced by the samples.  
The sample is placed in the instrument, in a thermally conductive container such as 
aluminum, upon a stage that is made from a quartz glass. A rigid, thin plate is placed to partially 
cover the sample within the crucible. The probe, also made of quartz glass, is placed in contact 
with the surface of a plate. The probe and the stage are made from Quartz glass because it has a 
relatively low, reproducible, and accurately known coefficient of thermal expansion. It also has a 
low thermal conductivity that aids in isolating the sensitive transducer from the changing 

























dynamic force in addition to the initial desired load.  
Gel Permeation Chromatography (GPC) 
Gel permeation chromatography (GPC) is a experimental technique used to separate 
mixtures according to a component’s molecular size. It consists of a mobile phase and a 
stationary phase. The mobile phase, which is capable of mass exchange, is a liquid that can 
readily dissolve the sample. The stationary phase is a porous material whose pore sizes are 
various sizes and separates the molecules based on their particle sizes. Porous structures are 
common in inorganic polymers (e.g. glass and silica gel) and in cross-linked organic polymers, 
usually in the swollen state.
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In a simple example of using GPC, shown in Figure 27, the column is packed with the 
swollen gel, a sample solution is poured in, and then the eluate is collected in fractions. The 
solvent flows from the reservoir through a sintered glass plate into a device that is used for 
degassing. The device is made up of an electrically heated metal block with an upright tube or a 
Liebig condenser heated by a thermostat-monitored liquid. When water is the eluent a peristaltic 
pump can be used, where as when the eluent is organic, piston pumps are more favorable. Also 
aqueous solutions may be injected through elastomer packing, where as organic samples have 
ball valves used instead.   
GPC Testing Procedure  
 Slowly increase the flow rate of the instrument from 0.1 to 1.0 ml/min in 0.1 






















 Completely dissolve sample (PLCL) in THF (Do not shake sample THF dissolves the 
material that lines the lid). Weigh the sample so that for every 2.5mg of PLCL 1 mL 
of Tetrahydrofuran (THF) is  added 
 When completely dissolved add one (1) drop of toluene (Toluene use to monitor to 
filtration process).  
 Clean syringe with small amount of sample possibly 0.2 mL and rotate syringe 
 Place more of sample in syringe and excrete until air bubbles are removed. 
 Place syringe filter on the tip of the syringe 
 Place sample in GPC and lock device. 
 Start Circus GPC/ Multi Detector Software Version 2 
 PL Data Stream Monitor (to monitor the data collection) 
Testing of the Portosystemic Shunt Occluder 
Testing of all the components associated with the shunt occluder (shunt occluder shell, 
swelling hydrogel- PAA, and degrading polymer-PLCL) was necessary to verify complete 
experimental function. The experimental setup can be seen in Figure 28. 
A Pulsatile Blood Pump was used to simulate the fluid flow (flow rate, systolic and 
diastolic pressure, volume) of a canine.  A water reservoir was the fluid source (input) for the 
blood pump. The output fluid of the blood pump flowed to a splitter which evenly divided the 
pressure and flow of the fluid output from the blood pump. By dividing the fluid flow into two 























five minute time period. The volume was measured in three separate trials per test date. Fluid 
flow rate though the synthetic vessel, and correspondingly the volume of water collected in a set 
flow ceased when the piston displacement was approximately 3mm. The vessel was constricted 
to have a closed (constricted) thickness of approximately 1mm. 
Procedure 
 Place PBS solution in beaker and then place the beaker on a heating plate 
 Set the temperature of the heating plate to 37oC 
 Place loaded (PAA and PLCL in the device) Portosystemic Shunt Occluder onto 
synthetic vessel.  
 Connect synthetic vessel to fluid flow as presented in Figure 28 
 Place shunt occluder in PBS solution (make sure polymeric chamber is completely 
submerged. 
 Turn on the Pulsatile Pump for a 5 minute interval  
 Collect water flow in separate beaker and measure with volumetric flask 
 Repeat test randomly as the portosystemic shunt occluder’s opening decreases ( note 










Testing was conducted on three different areas of focus to characterized the polymeric 
components of the shunt occluder: (1) the swelling hydrogel- poly (acrylic acid), (2) the 
degradation the degradation of the polymer- poly (lactide-co-caprolactone), and (3) the shunt 
occluder’s functioning. The pressure produced, the swelling ratio, and swelling rate of the poly 
(acrylic acid) were determined using a Thermal Mechanical Analyzer. The molecular weight 
degradation rate of two different compositions of poly (lactide-co-caprolactone) (40:60 and 
86:14) were determined by analyzing several samples in in-vitro conditions (pH-7.4 and 
temperature of 37
o
C ) and at an elevated temperature of 50
o
C. The final step of in-vitro testing 
was to test the portosystemic shunt occluder with the polymeric materials loaded in the device, 
Figure 20. The portosystemic shunt occluder, loaded with the poly (lactide-co-caprolactone) and 
poly (acrylic acid), was tested in in-vitro conditions by analyzing the occlusions effect on fluid 
volume change.  
PolyAcrylic Acid  
Approximately 8 mg of PAA was placed into a crucible of a 0.00533m diameter and a 
0.00952m height. A constant force of 13.45 N/m
2
 was applied by the probe on the surface of the 
plate, and the temperature was kept constant at 37
o
C in a nitrogen gas environment. 























information that can be obtained from this data includes the swelling rates, Table 2, and swelling 
ratio, Table 3. The data shows that 8 mg of PAA will produce a maximum displacement of 
approximately 5000 microns.  
Swelling Rate of Poly(acrylic acid) Hydrogel 
The swelling rates were determined for the PAA using equation 2. An average swelling 
rate of 0.071mm/s was obtained for the PAA hydrogel (Table 2). The PAA hydrogel loaded into 
the device would cause the piston to occlude a 4mm diameter vessel in 56.3 seconds, if the 
opposing force produced by the degrading polymer (Poly (lactide-co-caprolactone)) wasn’t 
present.  
The swelling ratio of the poly (acrylic acid) was determined by the following equation:  












  Equation 3 
QH is the swelling ratio of a cylindrical shaped the poly (acrylic acid) hydrogel sample. 
The radius of the vessel is r. Hf is the finial height of the hydrated poly (acrylic acid) in the 
cylindrical crucible used to hold the sample during the TMA testing. Ho is the initial height of 
the dehydrated PAA particles in the container. Table 3 summarizes the swelling ratios for five 
















Table 2: Swelling Rates of PAA Hydrogel 
Trial 1 (mm/s)  Trial 2 (mm/s)  Trial 3 (mm/s) Trial 4 (mm/s)  Trial 5 (mm/s)  
0.0796 0.066 0.055 0.085 0.0696 




























19.66 17.43 21.12 21.3 21 












Degradation Studies of Poly (Lactide-co-Caprolactone) Copolymers 
The degradation of two different molar compositions of poly (lactide-co-caprolactone) 
were analyzed using TMA.  As the copolymer degraded, by both random chain scission and 
specific chain scission, the molecular weight of the polymer decreased. The decrease in the 
molecular weight was monitored by analyzing the molecular weight by GPC of several PLCL 
samples of different molar composition at different intervals of time (approximately every two 
weeks) over a 42 day and 45 day period of analysis for the PLCL (40:60) and the PLCL (86:14), 
respectively.  
Poly (Lactide-co-Caprolactone) PLCL (40:60) 
The PLCL with a molar composition of 40% Lactide and 60 % Caprolactone was placed 
weight associated with the degradation of PLCL (40:60). The molecular weight degradation is 
presented in respect to the molecular weight of the residual polymer in Tables 4 and 5. 
The Poly (Lactide-co-caprolactone) (40:60) in the 37
o
 C environment degraded at a 
slower rate than the same composition, in the 50
o
C environment. After 42 days the PLCL 
samples at the 37
o
C temperature were at approximately 50% of their initial molecular weight, 
where as the PLCL samples at the 50
o
C temperature were degraded to approximately 18% of 
their initial molecular weight. 
Poly (Lactide-co-Caprolactone) PLCL (86:14)  
The PLCL with a molar composition of 86% lactide and 14% caprolactone was in PBS 















Days Mw Trial 1 Residual 1 (%) Mw Trial 2 Residual 2 (%) 
1 44299.0 100.00 44602.0 100.00 
13 35714.0 80.62 35760.5 80.18 
28 26931.0 60.79 28337.5 63.53 










Days Mw Trial 1 Residual 1 (%) Mw Trial 2 Residual 2 (%) 
1 57883.0 100.00 59106.0 100.00 
16 43262.0 74.74 43705.0 73.94 
30 19003.0 32.83 19070.0 32.26 










C, Tables 6 and 7 respectively. The PLCL (86:14) was analyzed using GPC to determine the 
of molecular weight changes. The PLCL 86:14 composition degraded at a faster rate than the 
PLCL (40:60) composition. In Tables 6 and 7, the percentage of the molecular weight that 
remained with respect to the initial molecular weight, residual, decreased with time progression 
of the two separate samples.  







C, over a 45 day period of time, the polymer degraded to approximately 5% of its initial 
molecular weight (Table 6) and at 50
o
C the PLCL (86:14) degraded to approximately 4% of its 
initial molecular weight (Table 7). There was little difference between the degradation time of 





Volumetric Fluid Flow through a Synthetic Vessel with an Occluding Portosystemic Shunt 
Occluder Present 
The loaded (with the degrading polymer poly (lactide-co-caprolactone) and swelling 
hydrogel poly (acrylic acid)) portosystemic shunt occluder was positioned around a synthetic 
vessel (Figure 20) and placed into a phosphate buffered saline (PBS) solution and kept at a 
temperature of 37
o
C. The piston displacement, distance that the piston shifted to occlude the 
vessel, was measured on the different days that the testing was performed. After the piston was 
allowed to move a significant distance (≥ 0.5 mm) a fluid flow test was performed to determine 
the change in volume of the water collected, Figure 28, as a result of the piston moving position 















Days Mw Trial 1 Residual 1 (%) Mw Trial 2 Residual 2 (%) 
1 97128 100.00 96513.5 100.00 
16 24890 25.63 24084 24.95 
31 8248 8.49 7873 8.16 
45 5142 5.29 4801 4.97 
 
 




Days Mw Trial 1 Residual 1(%) Mw Trial 2 Residual 2 (%) 
1 97128 100.00 96513.5 100.00 
16 15356 15.80 14778 15.31 
31 6803 7.00 6437 6.67 








There was a decrease in the fluid volume flowing through the vessel over approximately 
a 90-day period, at which time the flow was approximately zero (Table 8).  Volume of fluid was 
collected over a five minute intervals of time. The average volume of the collected fluid was 
determined and the flow rate through the occluding vessel was determined using Equations 4 and 





   Equation  4 
The distance between the piston portion of the portosystemic shunt occluder (Figure 21) 
and base of the vessel chamber decreased over time and correlatively the flow rate decreased. 
Figure 30 shows the average flow rates through the occluding vessel for several different days of 














Table 8: Fluid flow testing of Portosystemic Shunt Occluder 
 


































Swelling of Poly (acrylic acid) Hydrogel  
The analysis of the poly (acrylic acid) – PAA swelling properties was done using the 
Mettler Toledo Star System TGA/SDTA851e Module Thermogravitational Analysis instrument. 
The pressure and swelling characteristics of the PAA were determined from the TMA analysis, 
Figure 29.  PAA behavioral insight on how the swelling hydrogel would behave in the shunt 
occluder device was gained. Small opaque gel balls, that were soft and easily broken when 
rubbed between fingers, were formed when the PAA particles were hydrated. A set amount of 
unhydrated PAA was placed in a small capsule with a flat plate that acted as a contact surface for 
the quartz glass probe, in the TMA.  PBS was then placed into the container to initiate the 
swelling of the PAA, Figure 26. 
The swelling ratio of the hydrogel, polyacrylic acid, had been anticipated to be 
approximately 40 X its original size based on research conducted by Elliott et al.
37
 However, in 
testing the hydrogel (PAA-H), the swelling ratio exceeded approximately 20X the original size, 
Table 3.  The actual swelling ratio provided swelling results less than the theoretical but still 
more than enough to shift the piston into the desired position. The swelling rate of 0.071 mm/s 
was obtained from the slope of the linear graphs in Figure 28.   
The PAA generated a force greater 0.033N. The PAA had to overcome an applied force 






in Figure 29.  This is more than the force of 0.025 N required to occlude the vessel and 
significantly less than the force of 6.67 N that would cause mechanical failure of the device. The 
force needed to cause mechanical failure of the device was determined by physically testing the 
assembled device with loads (weights) applied. Mechanical failure occurred when a load of 24 
oz (0.6805kg) was applied. Using equation 5 the force that was applied to the occluder device to 
cause mechanical failure was 6.67.   




      Equation  5 
Force Generated by Poly(Acrylic Acid) Hydrogel 
The amount of pressure required to overcome the pressure generated by in a canine 
circulatory system is approximately 0.002N/mm
2
 (15 mm Hg).
7





 With this knowledge we are able to determine the force required by the 
swelling hydrogel (PAA) acting on the piston. The required force for the hydrogel to move the 
piston a distance of 4mm can be determined by Equation 6.  






















for other diameters, within 3-10 mm, to occlude the vessel can be seen in Table 9. The swelling 
ratios (QH) obtained from TMA investigation on multiple samples, are presented in Table 3.   
The average swelling ratio (QH) of the polymer with 8 mg of PAA was 20.10 ± 1.63 mm. 
The swelling ratio is determined from the height of the swollen PAA (Hf) divided by the height 
of the unswollen PAA (Ho), Equation 3.  The amount of swelling the PAA does determine the 
piston displacement and rate of displacement. The swelling ratios in Table 3 are capable of 
moving the piston (Figure 21) to occlude the vessel, depending on if the shunt is within the 3mm 
to 10mm range (Table 9). 
Molecular Weight Degradation 
Degradation to the Poly (caprolactone) (PCL) portion of the copolymer occurs in two 
ways, random chain scission and specific end chain scission. PCL undergoes degradation by pure 
specific chain end scission by unzipping from the hydroxyl end of the polymer under isothermal 
pyrolytic degradation and degrades thermally by random chain scission in solution.
62
 The PLA 
portion of the polymer composition degrades with ester interchange processes and 
decarboxylation from the chain ends.
62
  
A copolymer of poly(Lactide-co-caprolactone) (PLCL) degrades at a faster rate than the 
homopolymer. The decomposition temperature of PCL is 402
o
C, where as the decomposition 
temperature of PCL/PLA copolymer is 350
o
C. One of the reasons for the faster rate of 











Table 9: Force required to Close a Canine Shunt 
Force Required To Close a Canine Shunt 












degrades, influences the PCL
63
 A higher molar ratio of PLA in the copolymer composition leads 
to more lactic acid production during the degradation of the polymer. This leads to an increase 
the rate of degradation.  
Poly (Lactide-co-Caprolactone) PLCL (40:60) 
Gel Permeation Chromatography (GPC) results were obtained using a Polymer 
Laboratory PL-GPC20 Integrated GPC System. Two PL-gel 5um mixed C 300 x7.5mm columns 
were used in the instrument with a Knalier WellChrom K-2301 Refractive Index Detector. The 
solvent used in the instrument was Tetrahydrofuran (THF). 
The results presented in Tables 4 and 5 were obtained to determine the degradation rate 
of the PLCL (40:60) at 37
o
C (the temperature in a biological environment) and 50
o
C (elevated 
temperature to accelerate the degradation of the PLCL). Eight separate samples were prepared 
and placed into separate containers.  Four samples were prepared simultaneously and place in a 




C for each ratio. The molecular weights, Tables 4 
and 5, decreased over the 42-day period. 
PLCL (40:60), at 37
o
C, data extrapolated to 90 days (3 months) indicated a residual of 
40.7 % of the degrading polymer’s initial molecular weight would remain for the targeted time of 
the study, as shown in Table 10 and Figure 31.  The PLCL (40:60), at a temperature of 50
o
C, was 
predicted to degrade to 6.7% of its initial molecular weight after 90 days. The increase in 
temperature acted as a catalyst to increase the rate of degradation of the PLCL. The degradation 
at 37
o
C was compared to the rate of degradation of the 50
o











Table 10: Degradation /Extrapolation of PLCL (40:60) 
Day 
PLCL Residual 









1 98.983 114.240 
10 85.169 77.579 
20 72.070 50.466 
30 60.986 32.828 
40 51.606 21.355 
50* 43.669 13.891 
60* 36.953 9.036 
70* 31.269 5.878 
80* 26.460 3.824 
90* 22.390 2.487 




































































rates we could confirm proper degradation of the PLCL in the biological temperature of 37
o
C. 
The effect of an elevated temperature in a biological environment, possibly due to an infection or 
illness, on the device’s function (occluding of the shunt) could also be addressed.  
Poly (Lactide-co-Caprolactone) PLCL (86:14) 










C in a PBS Solution. The molecular weights decreased over the 45 day period. The initial 
molecular weight of PLCL (86:14) (Table 6 and 7) was greater than that of the PLCL (40:60) 
(Table 4 and 5).   
The PLCL with a molar composition of 86% lactide and 14% caprolactone was also 





PLCL (86:14) was analyzed using GPC to determine the of molecular weight degradation. The 
PLCL 86:14 composition degraded at a faster rate than PLCL 40:60 composition. In Tables 11, 
the percentage of the molecular weight that remained with respect to the initial molecular weight, 
residual, decreased with time progression of the two separate samples.   





Figure 32. At 37
o
C, over a 45 day period of time, the polymer degraded to approximately 5% of 
its initial molecular weight (Table 6) and at 50
o
C the PLCL (86:14) degraded to approximately 
4% of its initial molecular weight (Table 7). There was little difference between the degradation 













Table 11: Degradation/Extrapolation of PLCL (86:14) 
Day 
PLCL Residual  









1 82.984 71.962 
10 44.837 37.138 
20 22.624 17.807 
30 11.416 8.539 
40 5.760 4.094 
50* 2.906 1.963 
60* 1.466 0.941 
70* 0.740 0.451 
80* 0.373 0.216 
90* 0.188 0.103 






































































Comparison of Degradation Behavior of Copolymers 
PLCL (40:60 and 84:16) 
Sivalingam and Madras conducted a study to determine the thermal stability of a 
copolymer composed of PCL and PLA. From their results they noted that the PCL degrades from 
both random chain scission and specific chain end scission. The specific chain end scission leads 
to the formation of e-caprolactone with volatiles such as CO2. Sivalingam and Madras also came 
to the conclusion that at lower temperatures random chain scission dominates the degradation 
process and as the temperature increases the specific chain end scission (from the hydroxyl chain 
end portion of the chain) takes over and begins to dominate.  This lead to the conclusion that 
there is a change in degradation mechanisms in PCL as the temperature of the environment, that 
it is placed in, increases.  





C for both compositions of the polymer (40:60 and 84:16). The theoretical prediction was 
that the 40% lactide 60% caprolactone would degrade at a slower rate in both a biological 
temperature (37
o
C) and in an elevated temperature (50
o
C).  Figure 33 is a plot of the molecular 
weight degradation of the two compositions at a temperature of 37
o
C. Figure 34 is a comparison 
of the two different PLCL compositions (40:60 and 84:16) at 50
o
C.  The theoretical prediction 
for the PLCL (40:60)  was correct, as can be seen by a plot of the molecular weight at the 
different time spans. Though the PLCL (84:16) had a higher initial molecular weight than the 
PLCL (40:60), Tables 4 and 6, the molecular weight of the PLCL (84:16) was less than that of 












































Degradation of PLCL at 37oC

























Degradation of PLCL at 50oC






The molecular degradation rate of the PLCL (40:60) composition was slower than the molecular 
degradation rate of the PLCL (86:14) composition at an elevated temperature of 50
o
C. The PLCL 
(86:14) degraded to 15.31% of its initial molecular weight after 16 days; where as the PLCL 
(40:60) had only degraded to 73.94% of its initial molecular weight after the same amount of 
time. The 40:60 has a slower and more desirable rate of degradation than the PLCL (86:14). 
Effect of Temperature on the Molecular Degradation 
Poly (Lactide-co-Caprolactone) (40:60) 
As the environment’s temperature increases the rate of degradation also increase, Table 
12.The effect of temperature on the molecular degradation rate of the poly (lactide-co-
caprolactone) (40:60) polymer can be seen in Figure 35. At 37
o
C, after 10 days of degradation, 
the PLCL (40:60) had a degradation rate of 1.38 g/mol/day; where as at the same time (10 days) 
the PLCL (86:14) had a degradation rate of 3.67g/mol/day. The equation acquired, from 
analyzing the data plotted in Figure 35, can be used to predict the molecular degradation rate of 
the PLCL (40:60) at various temperatures.  
It can also be seen that the degradation rate decreased as the composition of the polymer 
degraded, Table 12. When the PLCL (40:60) was at 85.17% and 77% of its initial molecular 
weights their degradation rates were 1.38 g/mol/day and 3.66g/mol/day, but at lower molecular 
weights, 51.61% for the 37
o
C environment and 21.35% for the 50
o
C environment, the 


























10 1.381 3.666 
20 1.310 2.711 
30 1.108 1.764 
40 0.938 1.147 
50 0.794 0.746 
60 0.672 0.486 
70 0.568 0.316 
80 0.481 0.205 
90 0.407 0.134 













Figure 35: Molecular Degradation Rate in respect to temperature for PLCL (40:60) 
  




















































The degradation rate of the PLCL (40:60) had decreased by 32.1% within 40 days in the 37
o
C 




The effect of temperature on the molecular degradation rate of the poly (lactide-co-
caprolactone) (86:14) polymer can be seen in Table 13 and Figure 36. Unlike PLCL (40:60) as 




C the degradation rate decreased 
slightly, Figure 36. The effect of temperature on the molecular weight degradation rate for the 
PLCL (86:14) was different from what was expected. The rate of degradation was expected to 
increase as the temperature of the media increased. Unexpectedly, as the temperature of the 
media increased the rate of degradation slightly decreased, Figure 36. The difference in the 
molecular weight degradation rates were not significant enough (Table 13), therefore the effect 




C on the PLCL (86:14) composition can be neglected.  
Testing of the loaded Portosystemic Shunt Occluder 
A synthetic vessel was placed into the portosystemic shunt occluder. The shunt occluder 
was placed into phosphate buffer solution (PBS) that was keep at a temperature of 37
o
C. A 
schematic of the experimental setup can be seen in Figure 28.  As time progressed, the initial 
shunt occluder diameter of 4mm decreased until the synthetic vessel was completely constricted. 





















Degradation Rate of PLCL at 50
o
C 
 (g/mol/ day) 
10 3.814 3.482 
20 2.221 1.933 
30 1.120 0.926 
40 0.565 0.444 
50 0.285 0.213 
60 0.144 0.102 
70 0.072 0.049 
80 0.036 0.023 
90 0.018 0.011 




































































The goal of this project was to develop an implantable device that would slowly occlude 
a congenital single portosystemic shunt, which is a vessel in canines that is a genetic birth defect 
that causes blood to bypass the liver, over a 3-4 month (90-120 days) time. The reason for 
designing this device was because the current device that is used, the Ameroid Occluder, closes 
the vessel too rapidly and as a result it causes the system in which it is implanted to develop 
hypertension.. Hypertension results in development of multiple acquired shunts, which permit 
continued diversion of portal blood around the liver instead of through it. 
The new portosystemic device, that this project developed, was designed to be small 
(varies based on the shunt size it is designed for), biocompatible (materials compatible with 
biological system), light in weight (~1.15 g for a 4x4mm opening), simple (3 components, one of 
which that moves), and most importantly able to occlude the portosystemic shunt over a 3-4 
month (90-120 day) time span. The different components of the device (the swelling hydrogel-
PAA, the degrading polymer-PLCL, and the mechanical parts) were tested in separate stages.  
The PAA had a swelling ratio of 20.10 ± 1.63 and a swelling rate of 0.071mm/s
2
. It 
produces approximately 25mN of Force, which is more than the 8mN needed to occlude a vessel, 






degradation polymer was predicted to molecularly degrade significantly so that the mechanical 
properties of the polymer do not counter the force produced by the PAA after a 90 day time span 
in a 37
o
C environment. When the complete device was tested, Figure 30, the device occluded the 
synthetic vessel in 86 days. This is slightly shorter than the desired time range of 90 –120 days 
but the molar composition of the degradation polymer can be adjusted to change the time of 
occlusion.  
Proposed Future Work  
Additional testing needs to be conducted in an in-vivo environment before the device can 
be marketable. The in vivo testing will be potentially conducted by Dr. Tobias with the 
University of TN, School of Veterinary Medicine.  The testing conducted thus far has been in 
vitro and though it provides some incite to how the polymers and the device as a whole will 
behave in the biological environment, it does not account for enzymatic degradation, foreign 
body response, or the fluxing dynamic motions of a biological specimen. Animal testing needs to 
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